Table 1 Participant characteristic
Demographic data | |
|---|---|
Age (years) | 65 (57; 71) |
Sex (male) | 63% |
Body mass index (kg/m2) | 31.4 ± 5.6 |
Normal range (18–25) | 13% |
Overweight (25–30) | 27% |
Obese class I (30–35) | 36% |
Obese class II–III (> 35) | 24% |
Disease duration (years) | 10 (5; 17) |
Smoking habits | |
Current smoking (yes) | 3% |
Social smoking (yes) | 2% |
Previous smoking (yes) | 40% |
Medications | |
|---|---|
Antidiabetic medications (yes) | 93% |
Biguanides | 78% |
SGLT-2 inhibitors | 25% |
DPP-4 inhibitors | 18% |
Sulfonylureas | 9% |
Insulin (yes) | 26% |
Long-acting | 26% |
Dose (IU) | 50 (40; 92) |
Short-acting | 7% |
Dose (IU) | 22 (9; 100) |
Antihypertensives (yes) | 68% |
ACE-inhibitor | 32% |
β-blocker | 17% |
Statins (yes) | 70% |
Biochemistry | |
|---|---|
Fasting glucose levels (mmol/L) | 8.9 (7.5; 10.4) |
Haemoglobin A1c (mmol/mol) | 55 (48; 62) |
Cholesterol (mmol/L) | 3.9 ± 0.9 |
Triglyceride (mmol/L) | 1.4 (1.0; 2.0) |
Low density lipoprotein (mmol/L) | 1.9 (1.4; 2.4) |
High density lipoprotein (mmol/L) | 1.2 (1.0; 1.5) |
eGFR | 89 (73; 90) |
Creatinin | 8607 (5774; 13,190) |
Albumin | 0.01 (0.006; 0.019) |
ALAT | 27 (21; 37.5) |